Research programme: stroke therapeutics - Astellas Pharma/Quark Pharmaceuticals

Drug Profile

Research programme: stroke therapeutics - Astellas Pharma/Quark Pharmaceuticals

Alternative Names: FR-210575; Stroke research programme - Astellas Pharma/Quark Pharmaceuticals

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma; Quark Biotech
  • Developer Astellas Pharma; SBI Biotech
  • Class Cinnamates; Small molecules; Triazines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Stroke in USA
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 11 Aug 2003 Quark and Fujisawa have extended their research collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top